The relationship between diastolic blood pressure and coronary artery calcification is dependent on single nucleotide polymorphisms on chromosome 9p21.3

Table 1 Baseline characteristics of GENOA and FHS

	GENOA	FHS	P^‡
	N = 974	N = 1,140	P^‡
Age, years	58.41 (±10.17)	59.28 (±8.98)	0.67
Women, %	59.02%	54.35%	0.03
Participants with detectable CAC, %	68.60%	68.39%	0.92
ln(CAC score + 1)	2.88 (±2.56)	3.15 (±2.66)	0.16
Hypertension, %	72.17%	37.84%	<0.0001
Anti-hypertensive medication use, %	67.58%	27.83%	<0.0001
Systolic blood pressure, mmHg	131.20 (±16.87)	125.04 (±17.59)	<0.0001
Diastolic blood pressure, mmHg	74.26 (±9.16)	74.56 (±9.37)	0.60
Diabetes, %	13.96%	7.46%	<0.0001
Fasting glucose, mg/dL*	97.27 (±10.71)	96.66 (±9.78)	0.43
Past or Active tobacco use, %	45.26%	56.19%	0.0001
ln(Pack years + 1)	1.28 (±1.58)	2.56 (±1.01)	0.03
Statin Use, %†	24.57%	15.59%	<0.0001
LDL:HDL ratio	2.55 (±1.04)	2.56 (±1.01)	0.71

GENOA = Genetic Epidemiology Network of Arteriopathy; FHS = Framingham Heart Study Offspring cohort; CAC = coronary artery calcification; HDL = high density lipoprotein; LDL = low density lipoprotein; ln = natural logarithm; Statin = HMG-CoA Reductase Inhibitor.
*Fasting glucose mean and standard deviation calculated in subset of non-diabetics (GENOA: N = 844, FHS: N = 1054).
†Statin use was missing for 5 FHS participants.
^‡P-value from a linear mixed effects model to test the difference between the two cohorts’ means (quantitative traits) or the difference between the two cohorts’ frequencies (qualitative traits), accounting for sibship structure.

ISSN: 1471-2350